Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Digestive Diseases and Sciences
Published in: Digestive Diseases and Sciences 4/2022

01-04-2022 | Chronic Inflammatory Bowel Disease | Original Article

Functional Analysis of the Transcriptional Regulator IκB-ζ in Intestinal Homeostasis

Authors: Tomoki Sasaki, Hiroyuki Nagashima, Atsushi Okuma, Takeshi Yamauchi, Kenshi Yamasaki, Setsuya Aiba, Takanori So, Naoto Ishii, Yuji Owada, Takashi MaruYama, Shuhei Kobayashi

Published in: Digestive Diseases and Sciences | Issue 4/2022

Login to get access

Abstract

Background

The Toll-like receptor signaling pathway contributes to the regulation of intestinal homeostasis through interactions with commensal bacteria. Although the transcriptional regulator IκB-ζ can be induced by Toll-like receptor signaling, its role in intestinal homeostasis is still unclear.

Aims

To investigate the role of IκB-ζ in gut homeostasis.

Methods

DSS-administration induced colitis in control and IκB-ζ-deficient mice. The level of immunoglobulins in feces was detected by ELISA. The immunological population in lamina propria (LP) was analyzed by FACS.

Results

IκB-ζ-deficient mice showed severe inflammatory diseases with DSS administration in the gut. The level of IgM in the feces after DSS administration was less in IκB-ζ-deficient mice compared to control mice. Upon administration of DSS, IκB-ζ-deficient mice showed exaggerated intestinal inflammation (more IFN-g-producing CD4+ T cells in LP), and antibiotic treatment canceled this inflammatory phenotype.

Conclusion

IκB-ζ plays a crucial role in maintaining homeostasis in the gut.
Appendix
Available only for authorised users
Literature
1.
Kitamura H, Kanehira K, Okita K, Morimatsu M, Saito M. MAIL, a novel nuclear I kappa B protein that potentiates LPS-induced IL-6 production. FEBS Lett. 2000;485:53–56.PubMedCrossRef
2.
Motoyama M, Yamazaki S, Eto-Kimura A, Takeshige K, Muta T. Positive and negative regulation of nuclear factor-kappaB-mediated transcription by IkappaB-zeta, an inducible nuclear protein. J. Biol. Chem. 2005;280:7444–7451.PubMedCrossRef
3.
Yamazaki S, Muta T, Matsuo S, Takeshige K. Stimulus-specific induction of a novel nuclear factor-kappaB regulator, IkappaB-zeta, via Toll/Interleukin-1 receptor is mediated by mRNA stabilization. J. Biol. Chem. 2005;280:1678–1687.PubMedCrossRef
4.
Yamamoto M, Yamazaki S, Uematsu S et al. Regulation of Toll/IL-1-receptor-mediated gene expression by the inducible nuclear protein IkappaBzeta. Nature. 2004;430:218–222.PubMedCrossRef
5.
Shiina T, Konno A, Oonuma T et al. Targeted disruption of MAIL, a nuclear IkappaB protein, leads to severe atopic dermatitis-like disease. J Biol Chem. 2004;279:55493–55498.PubMedCrossRef
6.
Okuma A, Hoshino K, Ohba T et al. Enhanced apoptosis by disruption of the STAT3-IkappaB-zeta signaling pathway in epithelial cells induces Sjogren’s syndrome-like autoimmune disease. Immunity. 2013;38:450–460.PubMedCrossRef
7.
MaruYama T, Kobayashi S, Ogasawara K, Yoshimura A, Chen W, Muta T. Control of IFN-gamma production and regulatory function by the inducible nuclear protein IkappaB-zeta in T cells. J Leukoc Biol. 2015;98:385–393.PubMedPubMedCentralCrossRef
8.
Hanihara F, Takahashi Y, Okuma A, Ohba T, Muta T. Transcriptional and post-transcriptional regulation of IkappaB-zeta upon engagement of the BCR, TLRs and FcgammaR. Int Immunol. 2013;25:531–544.PubMedCrossRef
9.
Hanihara-Tatsuzawa F, Miura H, Kobayashi S et al. Control of Toll-like receptor-mediated T cell-independent type 1 antibody responses by the inducible nuclear protein IkappaB-zeta. J. Biol. Chem. 2014;289:30925–30936.PubMedPubMedCentralCrossRef
10.
Goto Y, Kurashima Y, Kiyono H. The gut microbiota and inflammatory bowel disease. Curr Opin Rheumatol. 2015;27:388–396.PubMedCrossRef
11.
Goto Y, Kiyono H. Epithelial barrier: an interface for the cross-communication between gut flora and immune system. Immunol Rev. 2012;245:147–163.PubMedCrossRef
12.
Hooper LV, Macpherson AJ. Immune adaptations that maintain homeostasis with the intestinal microbiota. Nat Rev Immunol. 2010;10:159–169.PubMedCrossRef
13.
Hamada H, Hiroi T, Nishiyama Y et al. Identification of multiple isolated lymphoid follicles on the antimesenteric wall of the mouse small intestine. J Immunol. 2002;168:57–64.PubMedCrossRef
14.
Bouskra D, Brezillon C, Berard M et al. Lymphoid tissue genesis induced by commensals through NOD1 regulates intestinal homeostasis. Nature. 2008;456:507–510.PubMedCrossRef
15.
16.
Bollrath J, Powrie FM. Controlling the frontier: regulatory T-cells and intestinal homeostasis. Semin Immunol. 2013;25:352–357.PubMedCrossRef
17.
Barmeyer C, Schulzke JD, Fromm M. Claudin-related intestinal diseases. Semin Cell Dev Biol. 2015;42:30–38.PubMedCrossRef
18.
19.
Kakiuchi N, Yoshida K, Uchino M et al. Frequent mutations that converge on the NFKBIZ pathway in ulcerative colitis. Nature. 2020;577:260–265.PubMedCrossRef
20.
Khounlotham M, Kim W, Peatman E et al. Compromised intestinal epithelial barrier induces adaptive immune compensation that protects from colitis. Immunity. 2012;37:563–573.PubMedPubMedCentralCrossRef
21.
Cario E, Gerken G, Podolsky DK. Toll-like receptor 2 enhances ZO-1-associated intestinal epithelial barrier integrity via protein kinase C. Gastroenterology. 2004;127:224–238.PubMedCrossRef
22.
Zhou W, Cao Q, Peng Y et al. FoxO4 inhibits NF-kappaB and protects mice against colonic injury and inflammation. Gastroenterology. 2009;137:1403–1414.PubMedCrossRef
23.
Al Alam D, Sala FG, Baptista S et al. FGF9-Pitx2-FGF10 signaling controls cecal formation in mice. Dev Biol. 2012;369:340–348.PubMedCrossRef
24.
25.
Gao R, Brigstock DR. A novel integrin alpha5beta1 binding domain in module 4 of connective tissue growth factor (CCN2/CTGF) promotes adhesion and migration of activated pancreatic stellate cells. Gut. 2006;55:856–862.PubMedPubMedCentralCrossRef
26.
Grainger JR, Askenase MH, Guimont-Desrochers F, da Fonseca DM, Belkaid Y. Contextual functions of antigen-presenting cells in the gastrointestinal tract. Immunol Rev. 2014;259:75–87.PubMedPubMedCentralCrossRef
27.
Nishikawa S, Honda K, Vieira P, Yoshida H. Organogenesis of peripheral lymphoid organs. Immunol Rev. 2003;195:72–80.PubMedCrossRef
28.
29.
Donaldson DS, Bradford BM, Artis D, Mabbott NA. Reciprocal regulation of lymphoid tissue development in the large intestine by IL-25 and IL-23. Mucosal Immunol. 2015;8:582–595.PubMedCrossRef
30.
Lorenz RG, Chaplin DD, McDonald KG, McDonough JS, Newberry RD. Isolated lymphoid follicle formation is inducible and dependent upon lymphotoxin-sufficient B lymphocytes, lymphotoxin beta receptor, and TNF receptor I function. J Immunol. 2003;170:5475–5482.PubMedCrossRef
31.
32.
Vijay-Kumar M, Wu H, Aitken J et al. Activation of toll-like receptor 3 protects against DSS-induced acute colitis. Inflammatory Bowel Diseases. 2007;13:856–864.PubMedCrossRef
33.
Hattori N, Niwa T, Ishida T et al. Antibiotics suppress colon tumorigenesis through inhibition of aberrant DNA methylation in an azoxymethane and dextran sulfate sodium colitis model. Cancer Sci. 2019;110:147–156.PubMed
34.
Hernández-Chirlaque C, Aranda CJ, Ocón B et al. Germ-free and Antibiotic-treated Mice are Highly Susceptible to Epithelial Injury in DSS Colitis. J Crohns Colitis. 2016;10:1324–1335.PubMedCrossRef
35.
Huang YL, Chassard C, Hausmann M, von Itzstein M, Hennet T. Sialic acid catabolism drives intestinal inflammation and microbial dysbiosis in mice. Nat Commun. 2015;6:8141.PubMedCrossRef
36.
Buchta CM, Bishop GA. Toll-like receptors and B cells: functions and mechanisms. Immunol Res. 2014;59:12–22.PubMedCrossRef
37.
MaruYama T, Sayama A, Ishii KJ, Muta T. Screening of posttranscriptional regulatory molecules of IkappaB-zeta. Biochem Biophys Res Commun. 2016;469:711–715.PubMedCrossRef
38.
Kirkland D, Benson A, Mirpuri J et al. B cell-intrinsic MyD88 signaling prevents the lethal dissemination of commensal bacteria during colonic damage. Immunity. 2012;36:228–238.PubMedPubMedCentralCrossRef
39.
Hobeika E, Thiemann S, Storch B et al. Testing gene function early in the B cell lineage in mb1-cre mice. Proc Natl Acad Sci U S A. 2006;103:13789–13794.PubMedPubMedCentralCrossRef
40.
Mennigen R, Nolte K, Rijcken E et al. Probiotic mixture VSL#3 protects the epithelial barrier by maintaining tight junction protein expression and preventing apoptosis in a murine model of colitis. Am J Physiol Gastrointest Liver Physiol. 2009;296:G1140-1149.PubMedCrossRef
41.
Phung HT, Nagashima H, Kobayashi S et al. TRAF5 deficiency ameliorates the severity of dextran sulfate sodium colitis by decreasing TRAF2 expression in nonhematopoietic cells. ImmunoHorizons. 2020;4:129–139.PubMedCrossRef
42.
Kawabe T, Sun SL, Fujita T et al. Homeostatic proliferation of naive CD4+ T cells in mesenteric lymph nodes generates gut-tropic Th17 cells. J Immunol. 2013;190:5788–5798.PubMedCrossRef
43.
Maruyama T, Li J, Vaque JP et al. Control of the differentiation of regulatory T cells and T(H)17 cells by the DNA-binding inhibitor Id3. Nat Immunol. 2011;12:86–95.PubMedCrossRef
44.
Metadata
Title
Functional Analysis of the Transcriptional Regulator IκB-ζ in Intestinal Homeostasis
Authors
Tomoki Sasaki
Hiroyuki Nagashima
Atsushi Okuma
Takeshi Yamauchi
Kenshi Yamasaki
Setsuya Aiba
Takanori So
Naoto Ishii
Yuji Owada
Takashi MaruYama
Shuhei Kobayashi
Publication date
01-04-2022
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 4/2022
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-021-06958-8

Other articles of this Issue 4/2022

Digestive Diseases and Sciences 4/2022 Go to the issue

Editorial

Covid-19 and Patients with IBD: Who Is at Highest Risk for Severe Complications?

Original Article

Visceral Adipose Tissue and Non-alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes

Review

Pharmacological Interventions for the Prevention and Treatment of Immune Checkpoint Inhibitor-Associated Enterocolitis: A Systematic Review

Original Article

Cost-Effectiveness of Empirical Bismuth-Based Quadruple Therapy and Tailored Therapy After Clarithromycin Resistance Tests for Helicobacter pylori Eradication

Review

Acute Diverticulitis in Young Patients: A Review of the Changing Epidemiology and Etiology

Original Article

Race Adjustment in eGFR Equations Does Not Improve Estimation of Acute Kidney Injury Events in Patients with Cirrhosis
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits